Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Clinical trial NCT04088110 · UNKNOWN

Trial details

NCT number: NCT04088110
Sponsor: Fuzhou General Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Cancer Female HER2-positive Breast Cancer Hormone Receptor Positive Malignant Neoplasm of Breast Metastatic Breast Cancer Breast Diseases Hormone Receptor Positive Tumor

Start date: 2019-11-01
Primary completion: 2021-11-01
Enrollment: 77

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.